Cargando…
Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355171/ https://www.ncbi.nlm.nih.gov/pubmed/22615848 http://dx.doi.org/10.1371/journal.pone.0036927 |
_version_ | 1782233342959157248 |
---|---|
author | Cohen, Jérémie F. Leis, Alexander Lecarpentier, Thibault Raymond, Josette Gendrel, Dominique Chalumeau, Martin |
author_facet | Cohen, Jérémie F. Leis, Alexander Lecarpentier, Thibault Raymond, Josette Gendrel, Dominique Chalumeau, Martin |
author_sort | Cohen, Jérémie F. |
collection | PubMed |
description | BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed to identify the best biological predictor of response to beta-lactam therapy in children hospitalized for CAP. METHODS: A retrospective, single-centre cohort study included all consecutive patients 1 month to 16 years old hospitalized in a teaching hospital in Paris, France, because of CAP empirically treated with a beta-lactam alone from 2003 to 2010. Uni- and multivariate analyses were used to study the ability of routine biological parameters available in the Emergency Department to predict a favourable response to beta-lactam (defined as apyrexia within 48 hours of treatment onset). RESULTS: Among the 125 included patients, 85% (106) showed a favourable response to beta-lactam. In multivariate logistic regression, we found procalcitonin (PCT) the only independent predictor of apyrexia (p = 0.008). The adjusted odds ratio for the decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). At ≥3 ng/mL, PCT had 55.7% sensitivity (45.7–65.3), 78.9% specificity (54.4–93.9), 93.7% positive predictive value (84.5–98.2), 24.2% negative predictive value (14.2–36.7), 2.64 positive likelihood ratio (1.09–6.42) and 0.56 negative likelihood ratio (0.41–0.77). In the 4 children with a PCT level ≥3 ng/mL and who showed no response to beta-lactam treatment, secondary pleural effusion had developed in 3, and viral co-infection was documented in 1. CONCLUSIONS: PCT is the best independent biologic predictor of favourable response to beta-lactam therapy in children hospitalized for CAP. Thus, a high PCT level is highly suggestive of pneumococcal aetiology. However, a 3-ng/mL cut-off does not seem compatible with daily medical practice, and additional research is needed to further define the role of PCT in managing CAP in children. |
format | Online Article Text |
id | pubmed-3355171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33551712012-05-21 Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia Cohen, Jérémie F. Leis, Alexander Lecarpentier, Thibault Raymond, Josette Gendrel, Dominique Chalumeau, Martin PLoS One Research Article BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed to identify the best biological predictor of response to beta-lactam therapy in children hospitalized for CAP. METHODS: A retrospective, single-centre cohort study included all consecutive patients 1 month to 16 years old hospitalized in a teaching hospital in Paris, France, because of CAP empirically treated with a beta-lactam alone from 2003 to 2010. Uni- and multivariate analyses were used to study the ability of routine biological parameters available in the Emergency Department to predict a favourable response to beta-lactam (defined as apyrexia within 48 hours of treatment onset). RESULTS: Among the 125 included patients, 85% (106) showed a favourable response to beta-lactam. In multivariate logistic regression, we found procalcitonin (PCT) the only independent predictor of apyrexia (p = 0.008). The adjusted odds ratio for the decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). At ≥3 ng/mL, PCT had 55.7% sensitivity (45.7–65.3), 78.9% specificity (54.4–93.9), 93.7% positive predictive value (84.5–98.2), 24.2% negative predictive value (14.2–36.7), 2.64 positive likelihood ratio (1.09–6.42) and 0.56 negative likelihood ratio (0.41–0.77). In the 4 children with a PCT level ≥3 ng/mL and who showed no response to beta-lactam treatment, secondary pleural effusion had developed in 3, and viral co-infection was documented in 1. CONCLUSIONS: PCT is the best independent biologic predictor of favourable response to beta-lactam therapy in children hospitalized for CAP. Thus, a high PCT level is highly suggestive of pneumococcal aetiology. However, a 3-ng/mL cut-off does not seem compatible with daily medical practice, and additional research is needed to further define the role of PCT in managing CAP in children. Public Library of Science 2012-05-17 /pmc/articles/PMC3355171/ /pubmed/22615848 http://dx.doi.org/10.1371/journal.pone.0036927 Text en Cohen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cohen, Jérémie F. Leis, Alexander Lecarpentier, Thibault Raymond, Josette Gendrel, Dominique Chalumeau, Martin Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title | Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title_full | Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title_fullStr | Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title_full_unstemmed | Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title_short | Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia |
title_sort | procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355171/ https://www.ncbi.nlm.nih.gov/pubmed/22615848 http://dx.doi.org/10.1371/journal.pone.0036927 |
work_keys_str_mv | AT cohenjeremief procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia AT leisalexander procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia AT lecarpentierthibault procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia AT raymondjosette procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia AT gendreldominique procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia AT chalumeaumartin procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia |